ALLMedicine Angioedema Center

May 25th, 2020 - Lanadelumab demonstrated efficacy in preventing HAE attacks in the phase 3 HELP Study. To assess time to onset of effect and long-term efficacy of lanadelumab, based on exploratory findings from the HELP Study. Eligible patients with HAE type I/II...

May 23rd, 2020 - Patients ≥65 years old with hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency may have an altered response to treatment and be at higher risk for treatment-related adverse events (AEs) due to comorbidities and polypharmacy. Inves...

May 22nd, 2020 - Hereditary angioedema due to deficiency of the C1-inhibitor (HAE-C1INH; MIM#106100) is a rare autosomal disorder and affected individuals are generally heterozygous for dominant negative variants in the SERPING1 gene. Homozygosity for SERPING1 pat...

May 21st, 2020 - Angioedema in COVID-19.|2020|Cohen AJ,DiFrancesco MF,Solomon SD,Vaduganathan M,|

May 17th, 2020 - Chronic spontaneous urticaria (CSU) is defined as the spontaneous development of itchy hives and/or angioedema due to known or unknown causes that last for at least 6 weeks. At any given time, CSU is believed to affect 0.5-1% of the global populat...

Jan 10th, 2018 - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. I...

Feb 25th, 2015 - This guidance for the management of patients with chronic urticaria and angioedema has been prepared by the Standards of Care Committee of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well ...

Apr 30th, 2014 - Theworkgroup was formed by the JTFPP to develop a practiceparameter to address the diagnosis and treatment of urticaria withor without angioedema. The chair, Jonathan Bernstein, MD,invited workgroup members to participate in the parameterdevelopme.

Apr 15th, 2014 - Despite its relatively common occurrence and life-threatening potential, the management of angioedema in the emergency department (ED) is lacking in terms of a structured approach. It is paramount to distinguish the different etiologies of angioed...

Jun 3rd, 2013 - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council ...

May 27th, 2020 - Promethazine HCl Suppositories, USP are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioe...

May 25th, 2020 - Lanadelumab demonstrated efficacy in preventing HAE attacks in the phase 3 HELP Study. To assess time to onset of effect and long-term efficacy of lanadelumab, based on exploratory findings from the HELP Study. Eligible patients with HAE type I/II...

May 23rd, 2020 - Patients ≥65 years old with hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency may have an altered response to treatment and be at higher risk for treatment-related adverse events (AEs) due to comorbidities and polypharmacy. Inves...

May 22nd, 2020 - Hereditary angioedema due to deficiency of the C1-inhibitor (HAE-C1INH; MIM#106100) is a rare autosomal disorder and affected individuals are generally heterozygous for dominant negative variants in the SERPING1 gene. Homozygosity for SERPING1 pat...

May 21st, 2020 - Angioedema in COVID-19.|2020|Cohen AJ,DiFrancesco MF,Solomon SD,Vaduganathan M,|

Dec 5th, 2019 - Discussion The standard therapy for ACEI-inducedangioedema continues to be airway management and discontinuation of medication. However, life-threatening progression of symptoms have led to the use of off-label therapies, including FFP and bradyki.

Jan 14th, 2019 - New Antimicrobials New tetracyclines and antimicrobials for influenza, malaria, onchocerciasis, smallpox, and more New Drugs for Seizures Stiripentol and cannabidiol approved for seizures associated with Lennox-Gastaut syndrome or Dravet syndrome ...

Nov 30th, 2018 - Action Points Patients with type I or type II hereditary angioedema (HAE) suffer from regular, unpredictable and life-disrupting attacks, and patients are in need of better drugs to control this lifelong disabling condition. Patients whose HAE is ...

Nov 28th, 2018 - NEW YORK (Reuters Health) - Treatment with lanadelumab significantly reduced attacks of hereditary angioedema (HAE) type I and II in the phase 3 randomized controlled HELP study, supporting its use as a prophylactic therapy for HAE, researchers sa...

Nov 27th, 2018 - Prophylactic treatment with lanadelumab (Takhzyro) prevented hereditary angioedema attacks and led to a clinically-meaningful impact on quality of life, according to the pivotal HELP trial that led to recent FDA approval. The monoclonal antibody c...